Mycophenolate Mofetil in Patients with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: a Prospective Pharmacokinetics and Clinical Study

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2013 Dec 6

PMID 24304103

Citations 5

Authors

B Chaigne

P Gatault

F Darrouzain

C Barbet

D Degenne

M Francois

P Szymanski

N Rabot

G Golea

E Diot

F Maillot

Y Lebranchu

H Nivet

G Paintaud

J-M Halimi

L Guillevin

M Buchler

Affiliations

Soon will be listed here.

Abstract

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) treatment strategy is based on immunosuppressive agents. Little information is available concerning mycophenolic acid (MPA) and the area under the curve (AUC) in patients treated for AAV. We evaluated the variations in pharmacokinetics for MPA in patients with AAV and the relationship between MPA-AUC and markers of the disease. MPA blood concentrations were measured through the enzyme-multiplied immunotechnique (C(0), C(30), C(1), C(2), C(3), C(4), C(6) and C(9)) to determine the AUC. Eighteen patients were included in the study. The median (range) MPA AUC(0-12) was 50·55 (30·9-105·4) mg/h/l. The highest coefficient of determination between MPA AUC and single concentrations was observed with C(3) (P < 0·0001) and C(2) (P < 0·0001) and with C(4) (P < 0·0005) or C(0) (P < 0·001). Using linear regression, the best estimation of MPA AUC was provided by a model including C(30), C(2) and C(4): AUC = 8·5 + 0·77 C(30) + 4·0 C(2) + 1·7 C(4) (P < 0·0001). Moreover, there was a significant relationship between MPA AUC(0-12) and lymphocyte count (P < 0·01), especially CD19 (P < 0·005), CD8 (P < 0·05) and CD56 (P < 0·05). Our results confirm the interindividual variability of MPA AUC in patients treated with MMF in AAV and support a personalized therapy according to blood levels of MPA.

Citing Articles

Usefulness of monitoring mycophenolic acid exposure in systemic sclerosis-related interstitial lung disease: a retrospective cohort study.

Milesi J, Sampol E, Benyamine A, Diai S, Coiffard B, Nieves A BMC Pulm Med. 2024; 24(1):537.

PMID: 39468495 PMC: 11520084. DOI: 10.1186/s12890-024-03361-7.

Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study.

Legendre P, Blanchet B, Porcher R, Berezne A, Allard M, London J J Scleroderma Relat Disord. 2022; 6(1):87-95.

PMID: 35382246 PMC: 8922638. DOI: 10.1177/2397198320944342.

A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Sobiak J, Resztak M Eur J Drug Metab Pharmacokinet. 2021; 46(6):721-742.

PMID: 34480746 PMC: 8599354. DOI: 10.1007/s13318-021-00713-0.

Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study.

Andreasson K, Neringer K, Wuttge D, Henrohn D, Marsal J, Hesselstrand R Arthritis Res Ther. 2020; 22(1):230.

PMID: 33023643 PMC: 7539387. DOI: 10.1186/s13075-020-02323-8.

The Presence of Renal IgG Deposits in Necrotizing Crescentic Glomerulonephritis Associated with ANCA Is Not Related to Worse Renal Clinical Outcomes.

Dudreuilh C, Fakhouri F, Vigneau C, Augusto J, Machet M, Rabot N Kidney Dis (Basel). 2020; 6(2):98-108.

PMID: 32309292 PMC: 7154286. DOI: 10.1159/000503969.

References

van Schaik R, van Agteren M, de Fijter J, Hartmann A, Schmidt J, Budde K . UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009; 86(3):319-27. DOI: 10.1038/clpt.2009.83. View

Van Hest R, Mathot R, Pescovitz M, Gordon R, Mamelok R, van Gelder T . Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006; 17(3):871-80. DOI: 10.1681/ASN.2005101070. View

Yeung J, Wang W, Chan L . Determination of mycophenolic acid level: comparison of high-performance liquid chromatography with homogeneous enzyme-immunoassay. Transplant Proc. 1999; 31(1-2):1214-5. DOI: 10.1016/s0041-1345(98)01968-x. View

Kofler S, Deutsch M, Bigdeli A, Shvets N, Vogeser M, Mueller T . Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009; 28(6):605-11. DOI: 10.1016/j.healun.2009.03.006. View

Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude F . Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999; 10(9):1965-71. DOI: 10.1681/ASN.V1091965. View

Walsh M, James M, Jayne D, Tonelli M, Manns B, Hemmelgarn B . Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007; 2(5):968-75. DOI: 10.2215/CJN.01200307. View

van Gelder T . Mycophenolate blood level monitoring: recent progress. Am J Transplant. 2009; 9(7):1495-9. DOI: 10.1111/j.1600-6143.2009.02678.x. View

McKinney E, Lyons P, Carr E, Hollis J, Jayne D, C Willcocks L . A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010; 16(5):586-91, 1p following 591. PMC: 3504359. DOI: 10.1038/nm.2130. View

Buchler M, Lebranchu Y, Beneton M, Le Meur Y, Heng A, Westeel P . Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther. 2005; 78(1):34-42. DOI: 10.1016/j.clpt.2005.03.005. View

10.

Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C . Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997; 63(1):39-47. DOI: 10.1097/00007890-199701150-00008. View

11.

Merkel P, Cuthbertson D, Hellmich B, Hoffman G, Jayne D, Kallenberg C . Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis. 2008; 68(1):103-6. PMC: 3139244. DOI: 10.1136/ard.2008.097758. View

12.

Tornatore K, Sudchada P, Dole K, Difrancesco R, Leca N, Gundroo A . Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. J Clin Pharmacol. 2011; 51(8):1213-22. DOI: 10.1177/0091270010382909. View

13.

Tornatore K, Venuto R, Logue G, Davis P . CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. J Med. 1998; 29(3-4):159-83. View

14.

Tadema H, Abdulahad W, Stegeman C, Kallenberg C, Heeringa P . Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS One. 2011; 6(9):e24315. PMC: 3167839. DOI: 10.1371/journal.pone.0024315. View

15.

Weber L, Shipkova M, Armstrong V, Wagner N, Schutz E, Mehls O . Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem. 2002; 48(3):517-25. View

16.

Miura M, Satoh S, Niioka T, Kagaya H, Saito M, Hayakari M . Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit. 2008; 30(1):52-9. DOI: 10.1097/FTD.0b013e31815f5416. View

17.

Eskin-Schwartz M, David M, Mimouni D . Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin. 2011; 29(4):555-9. DOI: 10.1016/j.det.2011.06.012. View

18.

Lamprecht P, Wieczorek S, Epplen J, Ambrosch P, Kallenberg C . Granuloma formation in ANCA-associated vasculitides. APMIS Suppl. 2009; (127):32-6. DOI: 10.1111/j.1600-0463.2009.02474.x. View

19.

Rupprecht K, Schmidt C, Raspe A, Schweda F, Shipkova M, Fischer W . Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009; 49(10):1196-201. DOI: 10.1177/0091270009344988. View

20.

Joy M, Hogan S, Jennette J, Falk R, Nachman P . A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005; 20(12):2725-32. DOI: 10.1093/ndt/gfi117. View